Compare

Drugs Made In America Acquisition II Corp. vs EQV Ventures Acquisition Corp. II vs Bain Capital GSS Investment Corp. vs Cantor Equity Partners IV, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Drugs Made In America Acquisition II Corp. DMII	EQV Ventures Acquisition Corp. II EVAC	Bain Capital GSS Investment Corp. BCSS	Cantor Equity Partners IV, Inc. CEPF
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	n/a	n/a
Revenue growth (YoY)	n/a	n/a	n/a	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	n/a	n/a
Net margin	n/a	n/a	n/a	n/a
Net income	$4.19M	$8.92M	n/a	$6.13M
EPS (Diluted)	n/a	n/a	n/a	n/a
Operating cash flow	-$1.02M	-$627.9K	n/a	-$62.9K
Free cash flow	n/a	n/a	n/a	n/a
Cash & equivalents	$223	$1.09M	$0	$25.0K
Total assets	$504.96M	$470.27M	$465.84M	$456.95M
Total liabilities	$17.80M	$18.13M	$16.39M	$95.4K
Shareholders' equity	-$17.77M	-$16.38M	-$15.20M	$142.4K
Return on year-end equity	n/a	n/a	n/a	n/m
Shares outstanding	13.70M	n/a	n/a	n/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Drugs Made In America Acquisition II Corp.	EQV Ventures Acquisition Corp. II	Bain Capital GSS Investment Corp.	Cantor Equity Partners IV, Inc.
Latest	n/a	n/a	n/a	n/a
1 year earlier	n/a	n/a	n/a	n/a
2 years earlier	n/a	n/a	n/a	n/a
3 years earlier	n/a	n/a	n/a	n/a
4 years earlier	n/a	n/a	n/a	n/a